Format
Items per page
Sort by

Send to:

Choose Destination

Search results

Items: 1 to 20 of 272

1.

Clinical activity of azacitidine in patients who relapse after allogeneic stem cell transplantation for acute myeloid leukemia.

Craddock C, Labopin M, Robin M, Finke J, Chevallier P, Yakoub-Agha I, Bourhis JH, Sengelov H, Blaise D, Luft T, Hallek M, Kröger N, Nagler A, Mohty M.

Haematologica. 2016 Apr 14. pii: haematol.2015.140996. [Epub ahead of print]

2.

Expanding transplant options to patients over 50 years- Improved outcome after reduced intensity conditioning mismatched-unrelated donor transplantation for patients with acute myeloid leukemia: A report from the Acute Leukemia Working Party of the EBMT.

Savani BN, Labopin M, Kröger N, Finke J, Ehninger G, Niederwieser D, Schwerdtfeger R, Bunjes D, Glass B, Socie' G, Ljungman P, Craddock C, Baron F, Ciceri F, Gorin NC, Esteve J, Schmid C, Giebel S, Mohty M, Nagler A.

Haematologica. 2016 Mar 11. pii: haematol.2015.138180. [Epub ahead of print]

3.

Greatly reduced risk of EBV reactivation in rituximab-experienced recipients of alemtuzumab-conditioned allogeneic HSCT.

Burns DM, Rana S, Martin E, Nagra S, Ward J, Osman H, Bell AI, Moss P, Russell NH, Craddock CF, Fox CP, Chaganti S.

Bone Marrow Transplant. 2016 Feb 22. doi: 10.1038/bmt.2016.19. [Epub ahead of print]

PMID:
26901708
4.

Association of Macroeconomic Factors With Nonrelapse Mortality After Allogeneic Hematopoietic Cell Transplantation for Adults With Acute Lymphoblastic Leukemia: An Analysis From the Acute Leukemia Working Party of the EBMT.

Giebel S, Labopin M, Ibatici A, Browne P, Czerw T, Socie G, Unal A, Kyrcz-Krzemien S, Bacigalupo A, Goker H, Potter M, Furness CL, McQuaker G, Beelen D, Milpied N, Campos A, Craddock C, Nagler A, Mohty M.

Oncologist. 2016 Mar;21(3):377-83. doi: 10.1634/theoncologist.2015-0314. Epub 2016 Feb 11.

PMID:
26869584
5.

Unrelated Cord Blood Transplantation in adults: evolution, experience and long-term outcomes in the UK National Health Service : a retrospective analysis on behalf of the British Society of Blood and Marrow Transplantation and Eurocord.

Snowden JA, Danby R, Ruggeri A, Marks DI, Hough RE, Pagliuca A, Potter M, Russell N, Craddock C, Clark A, Miller P, Cook G, Gluckman E, Shaw BE, Rocha V.

Br J Haematol. 2016 Feb;172(3):478-81. doi: 10.1111/bjh.13913. Epub 2015 Dec 27. No abstract available.

PMID:
26708833
6.

Recommendations for a standard UK approach to incorporating umbilical cord blood into clinical transplantation practice: an update on cord blood unit selection, donor selection algorithms and conditioning protocols.

Hough R, Danby R, Russell N, Marks D, Veys P, Shaw B, Wynn R, Vora A, Mackinnon S, Peggs KS, Crawley C, Craddock C, Pagliuca A, Cook G, Snowden JA, Clark A, Marsh J, Querol S, Parkes G, Braund H, Rocha V.

Br J Haematol. 2016 Feb;172(3):360-70. doi: 10.1111/bjh.13802. Epub 2015 Nov 18.

PMID:
26577457
7.

Influence of pre-existing invasive aspergillosis on allo-HSCT outcome: a retrospective EBMT analysis by the Infectious Diseases and Acute Leukemia Working Parties.

Penack O, Tridello G, Hoek J, Socié G, Blaise D, Passweg J, Chevallier P, Craddock C, Milpied N, Veelken H, Maertens J, Ljungman P, Cornelissen J, Thiebaut-Bertrand A, Lioure B, Michallet M, Iacobelli S, Nagler A, Mohty M, Cesaro S.

Bone Marrow Transplant. 2016 Mar;51(3):418-23. doi: 10.1038/bmt.2015.237. Epub 2015 Oct 26.

PMID:
26501769
8.

Psychological Stress of Hispanics Living on the Border.

Craddock CS, Folse KA.

J Immigr Minor Health. 2015 Oct 15. [Epub ahead of print]

PMID:
26472548
9.

Memory B-cell reconstitution following allogeneic hematopoietic stem cell transplantation is an EBV-associated transformation event.

Burns DM, Tierney R, Shannon-Lowe C, Croudace J, Inman C, Abbotts B, Nagra S, Fox CP, Chaganti S, Craddock CF, Moss P, Rickinson AB, Rowe M, Bell AI.

Blood. 2015 Dec 17;126(25):2665-75. doi: 10.1182/blood-2015-08-665000. Epub 2015 Oct 8.

10.

Exacerbation of IgA nephropathy following G-CSF administration for PBSC collection: suggestions for better donor screening.

Lee JB, Billen A, Lown RN, Potter MN, Craddock CF, de Lavallade H, Shaw BE, Sharpe CC.

Bone Marrow Transplant. 2016 Feb;51(2):286-7. doi: 10.1038/bmt.2015.224. Epub 2015 Oct 5. No abstract available.

PMID:
26437069
11.

In patients older than 55 years with AML in first CR, should we search for a matched unrelated donor when an old sibling donor is available?

Peffault de Latour R, Labopin M, Cornelissen J, Vigouroux S, Craddock C, Blaise D, Huyn A, Vindelov L, Maertens J, Chevallier P, Fegueux N, Socié G, Cahn JY, Petersen E, Schouten H, Lioure B, Russell N, Corral LL, Ciceri F, Nagler A, Mohty M; Acute Leukemia Working Party of EBMT.

Bone Marrow Transplant. 2015 Nov;50(11):1411-5. doi: 10.1038/bmt.2015.180. Epub 2015 Sep 14.

PMID:
26367237
12.

Tolerability and Clinical Activity of Post-Transplantation Azacitidine in Patients Allografted for Acute Myeloid Leukemia Treated on the RICAZA Trial.

Craddock C, Jilani N, Siddique S, Yap C, Khan J, Nagra S, Ward J, Ferguson P, Hazlewood P, Buka R, Vyas P, Goodyear O, Tholouli E, Crawley C, Russell N, Byrne J, Malladi R, Snowden J, Dennis M.

Biol Blood Marrow Transplant. 2016 Feb;22(2):385-90. doi: 10.1016/j.bbmt.2015.09.004. Epub 2015 Sep 9.

13.

Impact of the resolution of brain parcels on connectome-wide association studies in fMRI.

Bellec P, Benhajali Y, Carbonell F, Dansereau C, Albouy G, Pelland M, Craddock C, Collignon O, Doyon J, Stip E, Orban P.

Neuroimage. 2015 Dec;123:212-28. doi: 10.1016/j.neuroimage.2015.07.071. Epub 2015 Aug 1.

PMID:
26241681
14.

Prediction of Allogeneic Hematopoietic Stem-Cell Transplantation Mortality 100 Days After Transplantation Using a Machine Learning Algorithm: A European Group for Blood and Marrow Transplantation Acute Leukemia Working Party Retrospective Data Mining Study.

Shouval R, Labopin M, Bondi O, Mishan-Shamay H, Shimoni A, Ciceri F, Esteve J, Giebel S, Gorin NC, Schmid C, Polge E, Aljurf M, Kroger N, Craddock C, Bacigalupo A, Cornelissen JJ, Baron F, Unger R, Nagler A, Mohty M.

J Clin Oncol. 2015 Oct 1;33(28):3144-51. doi: 10.1200/JCO.2014.59.1339. Epub 2015 Aug 3.

PMID:
26240227
15.

Regulation of endomembrane biogenesis in arabidopsis by phospatidic acid hydrolase.

Craddock CP, Adams N, Bryant FM, Kurup S, Eastmond PJ.

Plant Signal Behav. 2015;10(10):e1065367. doi: 10.1080/15592324.2015.1065367. Epub 2015 Jul 30.

PMID:
26225871
16.

Acquired isodisomy on chromosome 13 at diagnosis results in impaired overall survival in patients with FLT3-ITD mutant acute myeloid leukaemia.

Loke JC, Akiki S, Borrow J, Ewing J, Bokhari SW, Chandra D, Arrazi J, Hazlewood P, Arthur K, Walsh J, Membwange Y, Wandroo FA, Watts A, Borg A, Brock K, Ferguson P, Craddock C, Griffiths M, Raghavan M.

Leukemia. 2015 Dec;29(12):2404-7. doi: 10.1038/leu.2015.148. Epub 2015 Jun 19. No abstract available.

PMID:
26172402
17.

Transfusion in CMV seronegative T-depleted allogeneic stem cell transplant recipients with CMV-unselected blood components results in zero CMV transmissions in the era of universal leukocyte reduction: a UK dual centre experience.

Hall S, Danby R, Osman H, Peniket A, Rocha V, Craddock C, Murphy M, Chaganti S.

Transfus Med. 2015 Dec;25(6):418-23. doi: 10.1111/tme.12219. Epub 2015 Jun 26.

PMID:
26114211
18.

Outcome of allogeneic hematopoietic stem-cell transplantation for adult patients with AML and 11q23/MLL rearrangement (MLL-r AML).

Pigneux A, Labopin M, Maertens J, Cordonnier C, Volin L, Socié G, Blaise D, Craddock C, Milpied N, Bacher U, Malard F, Esteve J, Nagler A, Mohty M; Acute Leukemia Working Party EBMT.

Leukemia. 2015 Dec;29(12):2375-81. doi: 10.1038/leu.2015.143. Epub 2015 Jun 17.

PMID:
26082270
19.

Guidelines for the diagnosis and management of acute myeloid leukaemia in pregnancy.

Ali S, Jones GL, Culligan DJ, Marsden PJ, Russell N, Embleton ND, Craddock C; British Committee for Standards in Haematology.

Br J Haematol. 2015 Aug;170(4):487-95. doi: 10.1111/bjh.13554. Epub 2015 Jun 17.

PMID:
26081614
20.

Conditioning intensity in middle-aged patients with AML in first CR: no advantage for myeloablative regimens irrespective of the risk group-an observational analysis by the Acute Leukemia Working Party of the EBMT.

Passweg JR, Labopin M, Cornelissen J, Volin L, Socié G, Huynh A, Tabrizi R, Wu D, Craddock C, Schaap N, Kuball J, Chevallier P, Cahn JY, Blaise D, Ghavamzadeh A, Bilger K, Ciceri F, Schmid C, Giebel S, Nagler A, Mohty M; Acute Leukemia Working Party of the European Blood and Marrow Transplant Group (EBMT).

Bone Marrow Transplant. 2015 Aug;50(8):1063-8. doi: 10.1038/bmt.2015.121. Epub 2015 Jun 1.

PMID:
26030052
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk